Danaher continues to charge exorbitant prices for lifesaving medical tests despite urgent demands for price reductions by several Ministries of Health
June 18, 2024Geneva, 17 June 2024 - In September 2023, the US corporation Danaher, which owns diagnostics maker Cepheid, announced a price reduction of the primary GeneXpert test used to diagnose tuberculosis (TB), from US$9.98 to $7.97, amid pressure from TB activists....
Read more
TB medicine deal offers short-term solution, but J&J needs to do more for all affected countries
July 14, 2023Christophe Perrin, TB advocacy pharmacist, MSF Access Campaign "Today's announcement by the Stop TB Partnership/Global Drug Facility about a deal with pharmaceutical corporation Johnson & Johnson (J&J), for access to affordable generic versions of the lifesaving tuberculosis (TB) drug bedaquiline, offers...
Read more
Access to medicines: Five people, five reasons we need to overcome monopolies on medicines
January 8, 2021Charles, Tobeka, Din, Nandita, and baby ‘Janey’. Four of these people have struggled for their lives. One of them has lost her life. All because pharma companies put profits before people. This is what can happen when companies get hold of patents and other...
Read more
Access to medicines
February 6, 2019Unaffordable, unavailable, not adapted - people around the world face these challenges in accessing lifesaving medicines. During the 1990s, MSF teams made a bitter observation: we were failing to treat some of our patients suffering from infectious diseases, while in...
Read more
